Navigation Links
New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
Date:4/19/2009

SYDNEY, April 20 /PRNewswire/ -- Australian medical research company Immune System Therapeutics Ltd (IST) has launched a clinical trial to test its breakthrough treatment for terminal blood cancers.

IST has genetically engineered an antibody drug that binds specifically to a target protein found on the surface of some blood cancer cells. Laboratory studies, using cells taken from patients with a type of blood cancer called multiple myeloma, have shown that the antibody works with the human immune system to induce death of the cancer cells. It is anticipated that the antibody will potentially reduce the number of cancerous cells in multiple myeloma patients and improve patient health and wellbeing.

IST has commenced a Phase 1 trial in patients with multiple myeloma and to date six patients have been treated at The Alfred Hospital in Melbourne under the supervision of Dr. Andrew Spencer. Results so far indicate that the antibody has no side effects and final results are expected later this year.

IST's Director of Clinical Development, Dr. Rosanne Dunn, said in order to maintain the recruitment momentum, the Company is seeking to enroll another nine multiple myeloma patients with the kappa form of the disease to be treated over the next few months.

"We are very pleased that the antibody drug is performing as expected with patients suffering no adverse effects. Although this is very rare in cancer treatment it is an indication that the antibody specifically targets cancer cells and not normal cells," she said.

IST's CEO, Mr. Alan Liddle, said multiple myeloma is a very debilitating terminal disease, with an estimated patient population of over 100,000 worldwide.

He said IST is undertaking further pre-clinical work on other blood cancers and diseases that are associated with the same target and could potentially be treated with the same antibody drug.

"If we continue to be successful in the current multiple myeloma trial, we expect to be able to move into other types of blood cancer in the coming year," Mr. Liddle said.

    For further information, please contact:

    Dr. Rosanne Dunn - +61 2 9514 4060
    Alan Liddle - +61 2 9514 7437
    Immune System Therapeutics
    www.ISTL.com.au


'/>"/>
SOURCE Immune System Therapeutics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Australian Technology: Detecting Breast Cancer With Hair
2. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
3. Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
4. Major deCODE-led Study Underscores Role of the Brain in Obesity
5. Isogen Launches Major New Facility to Address Global Biopharma Demand
6. MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy
7. Major State Grant Accelerates Research and Development of Novel Cancer Therapy
8. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
9. First Ever Study on Alzheimers Disease Treatment in Hispanics Presented at Major Medical Meeting
10. Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Südkorea, 23. Februar 2017 LG Innotek hat ... vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der ... im Bereich zwischen 200 und 280 nm und eignet sich ... indem es ihre DNA zerstört. Das Produkt von LG ... ...
(Date:2/23/2017)... ITL Limited, ( ASX: ITD ), an innovative diversified healthcare company, ... 31 December 2016 compared with the previous corresponding period. A full ... here . Highlights Profit ... Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; ... up 11%) Profit before tax of $2.12m (Dec ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of the ... their offering. ... research Menopause Drugs Price Analysis and Strategies - 2016, provides drug pricing ... the following questions: What are the key ... in the Global Menopause market? What are the unit ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and ... Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when he ... He explains that the Bible details the current times so plainly that anyone ...
(Date:2/24/2017)... ... , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently ... as the Chairman of the Management Committee when IFN was originally formed in 2002 ... of investor/owners and development of the business plan. He became the first paid ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... marketing services, which specializes in thought leadership , media relations, social media, ... and services that will be powered through Act-On, an intuitive marketing automation platform. ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... again hosted their Military Wedding Giveaway, with the winning couple announced on Feb. ... with services generously donated from local vendors: A Matter of Taste, Ryan Rousseau ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... jointly issued a letter to withdraw previous guidance issued by the ... identity. The guidance issued in May 2016 by the Obama Administration came in ...
Breaking Medicine News(10 mins):